Safety and effectiveness of a fixed-dose combination of olmesartan, Amlodipine, And hydrochlorothiazide in clinical practice

Vascular Health and Risk Management

Volumn 11, Issue , 2014, Pages 1-8

  Bramlage, Peter ^a   Fronk, Eva Maria ^b   Wolf, Wolf Peter ^b   Smolnik, RüDiger ^b   Sutton, Gemma ^a   Schmieder, Roland E ^c  

^a Institute für Pharmakologie und Präventive Medizin   (Germany)

^b DAIICHI SANKYO CO   (Japan)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Adverse drug reactions; Blood pressure; Clinical practice; Fixed dose combination; Hypertension

Indexed keywords

AMLODIPINE PLUS HYDROCHLOROTHIAZIDE PLUS OLMESARTAN; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; DRUG COMBINATION; HYDROCHLOROTHIAZIDE; IMIDAZOLE DERIVATIVE; OLMESARTAN; TETRAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; AUSTRIA; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CONNECTIVE TISSUE DISEASE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EAR DISEASE; ESSENTIAL HYPERTENSION; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; GERMANY; HEADACHE; HEART DISEASE; HUMAN; HYPOTENSION; INFECTION; INFESTATION; INNER EAR DISEASE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MENTAL DISEASE; METABOLIC DISORDER; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; OBSERVATIONAL STUDY; OPEN STUDY; PERIPHERAL EDEMA; PROSPECTIVE STUDY; RESPIRATORY TRACT DISEASE; RISK FACTOR; SKIN DISEASE; SYSTOLIC BLOOD PRESSURE; THORAX DISEASE; URINARY TRACT DISEASE; VASCULAR DISEASE; BLOOD PRESSURE; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECTS; HYPERTENSION; MIDDLE AGED; PATHOPHYSIOLOGY; PRIMARY HEALTH CARE; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGED; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; AUSTRIA; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIURETICS; DRUG COMBINATIONS; FEMALE; GERMANY; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; RISK FACTORS; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84919681868     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S75380     Document Type: Article

References (21)

1. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull. 1994;50:272-298.
2. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27:2121-2158.
3. Gradman AH. Rationale for triple-combination therapy for management of high blood pressure. J Clin Hypertens (Greenwich). 2010;12: 869-878.
4. Wright JT Jr, Dunn JK, Cutler JA, et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005;293:1595-1608.
5. Salahuddin A, Mushtaq M, Materson BJ. Combination therapy for hypertension 2013: an update. J Am Soc Hypertens. 2013;7:401-407.
6. Kizilirmak P, Berktas M, Uresin Y, Yildiz OB. The efficacy and safety of triple vs dual combination of angiotensin II receptor blocker and calcium channel blocker and diuretic: a systematic review and meta-analysis. J Clin Hypertens (Greenwich). 2013;15:193-200.
7. Neutel JM, Smith DH. Hypertension management: rationale for triple therapy based on mechanisms of action. Cardiovasc Ther. 2013;31: 251-258.
8. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159-2219.
9. Kjeldsen SE, Aksnes TA, Ruilope LM. Clinical implications of the 2013 ESH/ESC hypertension guidelines: targets, choice of therapy, and blood pressure monitoring. Drugs R D. 2014;14:31-43.
10. de la Sierra A, Barrios V. Blood pressure control with angiotensin receptor blocker-based three-drug combinations: key trials. Adv Ther. 2012;29:401-415.
11. Panjabi S, Lacey M, Bancroft T, Cao F. Treatment adherence, clinical outcomes, and economics of triple-drug therapy in hypertensive patients. J Am Soc Hypertens. 2013;7:46-60.
12. Bramlage P, Hasford J. Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment-a review. Cardiovas Diabetol. 2009;8:18.
13. Drugs@FDA [homepage on the Internet] Silver Spring: U.S. Food and Drug Administration; 2014. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/. Accessed November 21, 2014.
14. Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther. 2010;32:1252-1269.
15. Kereiakes DJ, Chrysant SG, Izzo JL Jr, et al. Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study. Cardiovasc Diabetol. 2012;11:134.
16. Punzi HA. Efficacy and safety of olmesartan/amlodipine/hydrochlorothiazide in patients with hypertension not at goal with mono, dual or triple drug therapy: results of the CHAMPiOn study. Ther Adv Cardiovasc Dis. 2014;8:12-21.
17. Volpe M, de la Sierra A, Ammentorp B, Laeis P. Open-label study assessing the long-term efficacy and safety of triple olmesartan/amlodipine/hydrochlorothiazide combination therapy for hypertension. Adv Ther. 2014;31:561-574.
18. Weir MR, Shojaee A, Maa JF. Efficacy of amlodipine/olmesartan medoxomil ± hydrochlorothiazide in patients aged $65 or,65 years with uncontrolled hypertension on prior monotherapy. Postgrad Med. 2013;125:124-134.
19. Ogihara T, Rakugi H, Ikegami H, Mikami H, Masuo K. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens. 1995;8:316-320.
20. Wang OJ, Krumholz HM. Clinical trial participation: are we studying the patients we are trying to treat? Eur J Heart Failure. 2009;11: 1021-1022.
21. Nallamothu BK, Hayward RA, Bates ER. Beyond the randomized clinical trial: the role of effectiveness studies in evaluating cardiovascular therapies. Circulation. 2008;118:1294-1303.